Strengths

Current ratio of 2.31 and quick ratio of 2.01 indicate better near-term liquidity than many small-cap medtech peers, reducing refinancing pressure in a capital-intensive sector.

Net debt to EBITDA of -0.78 implies net cash rather than leverage, giving MYO more balance-sheet flexibility than indebted peers during periods of weak operating performance.

Cash conversion cycle of 93 days is manageable for a device company with inventory and receivables, supporting working-capital control relative to peers with longer cycles.

Weaknesses

Return on invested capital of -45.2% shows capital is still destroying value, leaving MYO structurally weaker than profitable peers with positive reinvestment returns.

Debt to equity of 3.44 is elevated versus better-capitalized peers, indicating a more leveraged equity base despite the company’s net-cash position.

The absence of reported gross and operating margins limits evidence of operating leverage, while peers with scale typically show clearer margin durability.

Opportunities

If MYO converts its liquidity cushion into commercial execution, it can narrow the gap with peers that already monetize installed bases and recurring demand.

A net-cash balance sheet gives MYO more room than leveraged peers to fund product development, clinical evidence, and go-to-market expansion without immediate dilution pressure.

Working-capital discipline could improve as scale rises, allowing MYO to approach peer efficiency levels if receivables and inventory turnover tighten.

Threats

Persistent negative ROIC versus profitable peers suggests competitors can compound capital more efficiently, widening MYO’s structural disadvantage over a 2–5 year horizon.

High leverage on an equity basis leaves MYO more exposed than peers if operating losses persist, because financing flexibility can erode quickly.

A 93-day cash conversion cycle can pressure liquidity if demand slows, while peers with faster turnover can self-fund growth more reliably.

Overall Score

MYO’s liquidity is better than many peers, but deeply negative capital returns and limited operating evidence leave its structural positioning weak overall.